wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

CLPT, M.Pharmacy, Pharmaceutics; Regulatory Affairs

Total questions: 15

Worksheet time: 15mins

Name
Class
Date
1.

'IB' means:

a)

Investment Bond

b)

Investigator’s Bond

c)

Investigator’s Brochure

d)

Investment Brochure

2.

The Investigator’s Brochure (IB) is an important document, which is required as a part of the IND.

a)

True

b)

False

3.

The IB is a compilation of the ..................... data on the investigational product that are relevant to the trial of the product in human subjects.

a)

Clinical and nonclinical

b)

Nonclinical

c)

Clinical

d)

None

4.

Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol, such as the dose, dose frequency/interval, methods of administration, and safety monitoring procedures.

a)

True

b)

False

5.

The IB also provides insight to support the clinical management of the trial .................. during the course of the clinical trial.

a)

Applicant

b)

Sponsor

c)

Investigator

d)

Subjects

6.

The IB should be reviewed at least .................... and revised as necessary in compliance with a sponsor’s written procedures.

a)

Half yearly

b)

Annually

c)

Quarterly

d)

Two years

7.

Generally, the .................... is responsible for ensuring that an up-to-date IB is made available to the investigator(s).

a)

IRB

b)

USFDA

c)

sponsor

d)

Trail subject

8.

'IB' do not contain Physical, Chemical, and Pharmaceutical Properties and Formulation, details.

a)

True

b)

False

9.

'IB' also contain Nonclinical Pharmacology information.

a)

True

b)

False

10.

'IB' also contains Pharmacokinetics and Product Metabolism in Humans, information.

a)

True

b)

False

11.

'IMPD' means:

a)

Investigational Medicinal Process Dossier

b)

Investigational Medicinal Product Dose

c)

Investigational Medicinal Product Dossier

d)

Investigational Medicinal Product Disease

12.

The IMPD should contain information to justify the quality of any Investigational Medicinal Product (IMP) to be used in a clinical trial and include information on reference products and placebo.

a)

True

b)

False

13.

The IMPD should also provide data from nonclinical trials and any information on the previous clinical use of the IMP or justify in the application why information is not provided.

a)

True

b)

False

14.

An IMPD should not include summaries of information related to the quality, manufacture, and control of the IMP.

a)

True

b)

False

15.

IMPD should contain nonclinical pharmacology and toxicology data including summaries of nonclinical pharmacology and toxicology data for any IMP to be used in the clinical trial or justify why they have not.

a)

True

b)

False